|
Patient 1
|
Patient 2
|
Patient 3
|
Patient 4
|
Patient 5
|
---|
Age
|
59
|
67
|
50
|
56
|
49
|
Gender
|
Male
|
Male
|
Male
|
Male
|
Male
|
Year diagnosed NPC
|
2008
|
2007
|
2005
|
2010
|
2002
|
NPC stage
|
T3N2M0
|
T3N1M0
|
T3N0M0
|
T2N0M0
|
*
|
Treatment of NPC
|
RT
|
2008
|
2007
|
2005
|
2010
|
2002
|
70 Gy/35F
|
70 Gy/35F
|
Radical RT
|
70 Gy/35F
|
Yes*
|
2D
|
2D
|
2D
|
2D
|
2D
|
CT
|
DDP
|
DDP
|
DDP
|
DDP
|
Yes*
|
Date diagnosed NEC
|
2018/09/20
|
2020/03/09
|
2019/01/31
|
2020/04/29
|
2020/09/01
|
Sites of NEC
|
Left nasal cavity
|
Right hard palate
|
Left nasal cavity
|
Right nasal cavity-skull base
|
Left ethmoidal sinus
|
Treatment of NEC
|
ST
|
–
|
2020/03/06
|
2019/02/19
|
2020/04/23
|
2020/08/24
|
RT
|
GTV 70 Gy/33F
|
–
|
GTV 66 Gy/30F
|
GTV 64 Gy/30F
|
–
|
2018/10/23
|
–
|
2019/04/08
|
2020/05/25
|
–
|
IMRT
|
–
|
IMRT
|
IMRT
|
–
|
CT
|
VP
|
VP
|
VP
|
VP
|
GP
|
PFS
|
6 m
|
3 m
|
4 m
|
Censored
|
Censored
|
OS
|
9 m
|
3 m
|
9 m
|
Alive
|
Alive
|
- NEC, neuroendocrine carcinoma; NPC, nasopharyngeal carcinoma; OS, overall survival; IMRT, intensity modulated radiation therapy; RT, radiotherapy; CT, chemotherapy; ST, surgery therapy; GP, gemcitabine + DDP (cisplatin); VP, VP16 (etoposide) + DDP (cisplatin); 2D, two-dimensional radiotherapy
- –, not performed; *, no exact details